Bristol-Myers Squibb Co. (BMY)

Statement of Financial Position, Liabilities and Stockholders' Equity
Quarterly Data

Difficulty: Beginner

Annual Data

Quarterly Data

The statement of financial position provides creditors, investors, and analysts with information on company's resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company's assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Bristol-Myers Squibb Co., Consolidated Statement of Financial Position, Liabilities and Stockholders' Equity (quarterly data)

USD $ in millions

		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017		Jun 30, 2017		Mar 31, 2017		Dec 31, 2016		Sep 30, 2016		Jun 30, 2016		Mar 31, 2016		Dec 31, 2015		Sep 30, 2015		Jun 30, 2015		Mar 31, 2015		Dec 31, 2014		Sep 30, 2014		Jun 30, 2014		Mar 31, 2014		Dec 31, 2013		Sep 30, 2013		Jun 30, 2013		Mar 31, 2013
	Short-term debt obligations
	Accounts payable
	Accrued liabilities
	Deferred income
	Income taxes payable
	Liabilities related to assets held-for-sale
	Current liabilities
	Deferred income
	Income taxes payable
	Deferred income taxes
	Pension and other liabilities
	Long-term debt, excluding current portion
	Noncurrent liabilities
	Total liabilities
	Preferred stock
	Common stock
	Capital in excess of par value of stock
	Accumulated other comprehensive loss
	Retained earnings
	Cost of treasury stock
	Total Bristol-Myers Squibb Company shareholders' equity
	Noncontrolling interest
	Total equity
	Total liabilities and equity

Source: Bristol-Myers Squibb Co., Quarterly and Annual Reports

Item	Description	The company
Accounts payable	Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).	Bristol-Myers Squibb Co.'s accounts payable declined from Q4 2017 to Q1 2018 but then slightly increased from Q1 2018 to Q2 2018.
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Bristol-Myers Squibb Co.'s current liabilities increased from Q4 2017 to Q1 2018 and from Q1 2018 to Q2 2018.
Noncurrent liabilities	Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.	Bristol-Myers Squibb Co.'s noncurrent liabilities declined from Q4 2017 to Q1 2018 and from Q1 2018 to Q2 2018.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Bristol-Myers Squibb Co.'s total liabilities declined from Q4 2017 to Q1 2018 but then slightly increased from Q1 2018 to Q2 2018.
Total Bristol-Myers Squibb Company shareholders' equity	Total of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest).	Bristol-Myers Squibb Co.'s total Bristol-Myers Squibb Company shareholders' equity increased from Q4 2017 to Q1 2018 but then slightly declined from Q1 2018 to Q2 2018.
Total equity	Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity.	Bristol-Myers Squibb Co.'s total equity increased from Q4 2017 to Q1 2018 but then slightly declined from Q1 2018 to Q2 2018.

	Bristol-Myers Squibb Co.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

Bristol-Myers Squibb Co. (BMY)

Statement of Financial Position, Liabilities and Stockholders' EquityQuarterly Data

Statement of Financial Position, Liabilities and Stockholders' Equity
Quarterly Data